Targeting fibroblast derived thrombospondin 2 disrupts an immune-exclusionary environment at the tumor front in colorectal cancer.
Iwane K, Nakanishi Y, Muta Y, Chen J, Yasumura K, Omatsu M, Aoyama N, Ikeda M, Masui Y, Cai L, Yamakawa G, Hamada K, Mizukoshi K, Kawai M, Iimori K, Nakayama S, Agatsuma N, Utsumi T, Nagao M, Maruno T, Hiramatsu Y, Kakiuchi N, Nakagawa MM, Fukui Y, Kusunoki Y, Kasashima H, Fujimoto M, Itatani Y, Kogame T, Fukuda A, Yashiro M, Maeda K, Kabashima K, Obama K, Ogawa S, Diaz-Meco MT, Moscat J, Seno H.
Iwane K, et al. Among authors: nakayama s.
Nat Commun. 2025 Nov 23;16(1):11590. doi: 10.1038/s41467-025-66485-2.
Nat Commun. 2025.
PMID: 41276505
Free PMC article.